vs
Apellis Pharmaceuticals, Inc.（APLS）与CATO CORP（CATO）财务数据对比。点击上方公司名可切换其他公司
Apellis Pharmaceuticals, Inc.的季度营收约是CATO CORP的1.3倍（$199.9M vs $155.4M），CATO CORP净利率更高（-3.3% vs -29.5%，领先26.1%），CATO CORP同比增速更快（6.3% vs -5.9%），CATO CORP自由现金流更多（$-12.9M vs $-14.3M），过去两年Apellis Pharmaceuticals, Inc.的营收复合增速更高（7.7% vs -5.7%）
Apellis Pharmaceuticals是一家临床阶段生物制药企业，专注于开发调节补体系统的靶向疗法，适应症覆盖年龄相关性黄斑变性继发地图样萎缩等眼科疾病、罕见血液病及自身免疫性疾病，核心市场为美国及欧盟地区。
凯拓集团（Cato Corporation）是美国女性时装及配饰零售商，总部位于北卡罗来纳州夏洛特市。截至2016年1月，该公司旗下共运营1372家门店，覆盖Cato、Cato Plus、It's Fashion、It's Fashion Metro与Versona多个品牌。
APLS vs CATO — 直观对比
营收规模更大
APLS
是对方的1.3倍
$155.4M
营收增速更快
CATO
高出12.3%
-5.9%
净利率更高
CATO
高出26.1%
-29.5%
自由现金流更多
CATO
多$1.4M
$-14.3M
两年增速更快
APLS
近两年复合增速
-5.7%
损益表 — Q4 FY2025 vs Q3 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $199.9M | $155.4M |
| 净利润 | $-59.0M | $-5.2M |
| 毛利率 | — | 32.7% |
| 营业利润率 | -25.6% | -5.3% |
| 净利率 | -29.5% | -3.3% |
| 营收同比 | -5.9% | 6.3% |
| 净利润同比 | -62.2% | 65.6% |
| 每股收益（稀释后） | $-0.40 | $-0.28 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收APLSCATO
| Q4 25 | $199.9M | $155.4M | ||
| Q3 25 | $458.6M | $176.5M | ||
| Q2 25 | $178.5M | $170.2M | ||
| Q1 25 | $166.8M | $157.9M | ||
| Q4 24 | $212.5M | $146.2M | ||
| Q3 24 | $196.8M | $168.6M | ||
| Q2 24 | $199.7M | $177.1M | ||
| Q1 24 | $172.3M | $174.9M |
净利润APLSCATO
| Q4 25 | $-59.0M | $-5.2M | ||
| Q3 25 | $215.7M | $6.8M | ||
| Q2 25 | $-42.2M | $3.3M | ||
| Q1 25 | $-92.2M | $-14.1M | ||
| Q4 24 | $-36.4M | $-15.1M | ||
| Q3 24 | $-57.4M | $95.0K | ||
| Q2 24 | $-37.7M | $11.0M | ||
| Q1 24 | $-66.4M | — |
毛利率APLSCATO
| Q4 25 | — | 32.7% | ||
| Q3 25 | — | 36.8% | ||
| Q2 25 | — | 35.8% | ||
| Q1 25 | — | 29.2% | ||
| Q4 24 | — | 29.6% | ||
| Q3 24 | — | 35.3% | ||
| Q2 24 | — | 36.5% | ||
| Q1 24 | — | 32.1% |
营业利润率APLSCATO
| Q4 25 | -25.6% | -5.3% | ||
| Q3 25 | 48.7% | 3.1% | ||
| Q2 25 | -18.6% | 2.0% | ||
| Q1 25 | -50.0% | -15.2% | ||
| Q4 24 | -12.3% | -11.6% | ||
| Q3 24 | -24.0% | -0.4% | ||
| Q2 24 | -14.7% | 3.5% | ||
| Q1 24 | -36.0% | -9.5% |
净利率APLSCATO
| Q4 25 | -29.5% | -3.3% | ||
| Q3 25 | 47.0% | 3.9% | ||
| Q2 25 | -23.6% | 1.9% | ||
| Q1 25 | -55.3% | -8.9% | ||
| Q4 24 | -17.1% | -10.3% | ||
| Q3 24 | -29.2% | 0.1% | ||
| Q2 24 | -18.9% | 6.2% | ||
| Q1 24 | -38.5% | — |
每股收益（稀释后）APLSCATO
| Q4 25 | $-0.40 | $-0.28 | ||
| Q3 25 | $1.67 | $0.35 | ||
| Q2 25 | $-0.33 | $0.17 | ||
| Q1 25 | $-0.74 | $-0.73 | ||
| Q4 24 | $-0.30 | $-0.79 | ||
| Q3 24 | $-0.46 | $0.01 | ||
| Q2 24 | $-0.30 | $0.54 | ||
| Q1 24 | $-0.54 | $-1.15 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $466.2M | $79.0M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $370.1M | $167.6M |
| 总资产 | $1.1B | $450.2M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资APLSCATO
| Q4 25 | $466.2M | $79.0M | ||
| Q3 25 | $479.2M | $90.8M | ||
| Q2 25 | $370.0M | $80.0M | ||
| Q1 25 | $358.4M | $77.7M | ||
| Q4 24 | $411.3M | $86.2M | ||
| Q3 24 | $396.9M | $104.7M | ||
| Q2 24 | $360.1M | $105.4M | ||
| Q1 24 | $325.9M | $103.0M |
总债务APLSCATO
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | $93.1M | — |
股东权益APLSCATO
| Q4 25 | $370.1M | $167.6M | ||
| Q3 25 | $401.2M | $172.2M | ||
| Q2 25 | $156.3M | $164.9M | ||
| Q1 25 | $164.2M | $162.3M | ||
| Q4 24 | $228.5M | $177.1M | ||
| Q3 24 | $237.1M | $195.1M | ||
| Q2 24 | $264.3M | $196.9M | ||
| Q1 24 | $266.7M | $192.3M |
总资产APLSCATO
| Q4 25 | $1.1B | $450.2M | ||
| Q3 25 | $1.1B | $436.9M | ||
| Q2 25 | $821.4M | $440.8M | ||
| Q1 25 | $807.3M | $452.4M | ||
| Q4 24 | $885.1M | $424.4M | ||
| Q3 24 | $901.9M | $455.6M | ||
| Q2 24 | $904.5M | $477.1M | ||
| Q1 24 | $831.9M | $486.8M |
负债/权益比APLSCATO
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | 0.35× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-14.2M | $-12.4M |
| 自由现金流经营现金流 - 资本支出 | $-14.3M | $-12.9M |
| 自由现金流率自由现金流/营收 | -7.1% | -8.3% |
| 资本支出强度资本支出/营收 | 0.1% | 0.3% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $45.0M | $-7.5M |
8季度趋势，按日历期对齐
经营现金流APLSCATO
| Q4 25 | $-14.2M | $-12.4M | ||
| Q3 25 | $108.5M | $11.8M | ||
| Q2 25 | $4.4M | $3.9M | ||
| Q1 25 | $-53.4M | $-6.5M | ||
| Q4 24 | $19.4M | $-22.1M | ||
| Q3 24 | $34.1M | $3.1M | ||
| Q2 24 | $-8.3M | $5.7M | ||
| Q1 24 | $-133.0M | $-11.2M |
自由现金流APLSCATO
| Q4 25 | $-14.3M | $-12.9M | ||
| Q3 25 | $108.3M | $10.4M | ||
| Q2 25 | $4.4M | $2.8M | ||
| Q1 25 | $-53.4M | $-7.8M | ||
| Q4 24 | $19.3M | $-23.8M | ||
| Q3 24 | — | $1.6M | ||
| Q2 24 | $-8.4M | $2.4M | ||
| Q1 24 | $-133.3M | $-13.5M |
自由现金流率APLSCATO
| Q4 25 | -7.1% | -8.3% | ||
| Q3 25 | 23.6% | 5.9% | ||
| Q2 25 | 2.5% | 1.7% | ||
| Q1 25 | -32.0% | -5.0% | ||
| Q4 24 | 9.1% | -16.3% | ||
| Q3 24 | — | 0.9% | ||
| Q2 24 | -4.2% | 1.4% | ||
| Q1 24 | -77.3% | -7.7% |
资本支出强度APLSCATO
| Q4 25 | 0.1% | 0.3% | ||
| Q3 25 | 0.0% | 0.8% | ||
| Q2 25 | 0.0% | 0.6% | ||
| Q1 25 | 0.0% | 0.9% | ||
| Q4 24 | 0.0% | 1.2% | ||
| Q3 24 | 0.0% | 0.9% | ||
| Q2 24 | 0.0% | 1.8% | ||
| Q1 24 | 0.2% | 1.3% |
现金转化率APLSCATO
| Q4 25 | — | — | ||
| Q3 25 | 0.50× | 1.72× | ||
| Q2 25 | — | 1.17× | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 32.95× | ||
| Q2 24 | — | 0.52× | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
APLS
| Syfovre | $155.2M | 78% |
| Empaveli Pegcetacoplan | $35.1M | 18% |
| Licensing And Other Revenue | $9.6M | 5% |
CATO
| Retail Segment | $154.7M | 100% |
| Credit Card | $5.3M | 3% |
